Evidence map›Paper›PMID 27511219›Full record

ArticlePathology oncology research : POR2017

Variations in EGFR ctDNA Correlates to the Clinical Efficacy of Afatinib in Non Small Cell Lung Cancer with Acquired Resistance.

Jinfeng He, Wei Tan, Xuelian Tang, Jingping Ma

Abstract read
PubMed Publisher
In one paragraph

Article in Pathology oncology research : POR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Observational
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Circulating tumour DNA inCurrent oncology (Toronto, Ont.) · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jinfeng HeDepartment of Respiratory Medicine, Jingzhou Central Hospital, The Second Clinical Medical College, Yangtze University, Renmin Road 1, 434020, Jingzhou, People's Republic of China.
Wei TanHaemodialysis Centre, Jingzhou Central Hospital, The Second Clinical Medical College, Yangtze University, Jingzhou, People's Republic of China.
Xuelian TangDepartment of Respiratory Medicine, Jingzhou Central Hospital, The Second Clinical Medical College, Yangtze University, Renmin Road 1, 434020, Jingzhou, People's Republic of China.
Jingping MaDepartment of Respiratory Medicine, Jingzhou Central Hospital, The Second Clinical Medical College, Yangtze University, Renmin Road 1, 434020, Jingzhou, People's Republic of China. mjpjzhospital@hotmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monitoring of non small cell lung cancer (NSCLC) patients on afatinib after acquired resistance to 1

Indexed as

AfatinibBiomarkers, TumorCarcinoma, Non-Small-Cell LungDNA, NeoplasmDrug Resistance, NeoplasmErbB ReceptorsFemaleHumansLung NeoplasmsMaleMiddle AgedMutationProtein Kinase InhibitorsQuinazolinesAfatinibBiomarkers, TumorDNA, NeoplasmErbB ReceptorsProtein Kinase InhibitorsQuinazolinesAcquired resistanceAfatinibctDNAEGFR mutationsNon small cell lung cancer (NSCLC)

Identifiers

PMID27511219

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.